Reticulocyte invasion by Plasmodium vivax requires interaction of the Duffy-binding protein (PvDBP) with host Duffy antigen receptor for chemokines (DARCs). The binding domain of PvDBP maps to a cysteine-rich region referred to as region II (PvDBPII). Blocking this interaction offers a potential path to prevent P. vivax blood-stage growth and P. vivax malaria. This forms the rationale for development of a vaccine based on PvDBPII. Here we report results of a Phase I randomized trial to evaluate the safety and immunogenicity of recombinant PvDBPII formulated with glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE). Thirty-six malaria-naive, healthy Indian male subjects aged 18–45 years were assigned into three cohorts corresponding to doses of 10, 25 and 50 µg of PvDBPII formulated with 5 µg of GLA-SE. Each cohort included nine PvDBPII/GLA-SE vaccinees and three hepatitis B control vaccine recipients. Each subject received the assigned vaccine intramuscularly on days 0, 28 and 56, and was followed up till day 180. No serious AE was reported and PvDBPII/GLA-SE was well-tolerated and safe. Analysis by ELISA showed that all three doses of PvDBPII elicited antigen-specific binding-inhibitory antibodies. The 50 µg dose elicited antibodies against PvDBPII that had the highest binding-inhibitory titres and were most persistent. Importantly, the antibody responses were strain transcending and blocked receptor binding of diverse PvDBP alleles. These results support further clinical development of PvDBPII/GLA-SE to evaluate efficacy against sporozoite or blood-stage challenge in controlled human malaria infection (CHMI) models and against natural P. vivax challenge in malaria endemic areas.
AIM AND OBJECTIVES:To establish the prevalence and association of hypothyroidism in women affected with unexplained recurrent miscarriages. MATERIAL AND METHODS: This is an Observational case control study conducted in Obstetrics and Gynecology Department of NIMS Medical College and Hospital, Jaipur (Rajasthan); between July 2011 to June 2012.One hundred nonpregnant women with history of recurrent pregnancy losses were included in study group and one hundred non-pregnant women of similar age group with at least one successful pregnancy outcome were taken as control. All women who had known Thyroid disorder, diabetes, collagen and heart disease, were excluded from study. Detailed history, thorough physical examination was done and subjected to the quantitative estimation of triiodothyronine {T3}, Thyroxin {T4} and TSH hormone by CLIA method. RESULT: In the study 63% women experienced two or more pregnancy loss while 37% presented with three or more pregnancy losses. Total 7 patients were reported to have hypothyroidism out of which 3 were observed with subclinical hypothyroidism while 4 were detected overt hypothyroidism. In Control group 2 patient of subclinical hypothyroidism were detected. CONCLUSION: Prevalence of Hypothyroidism was 7 % and it has a statistically significant relationship with recurrent pregnancy losses in <20 weeks of gestation. Screening for thyroid dysfunction should be done early in pregnancy. Looking at the high percentage of abnormal TSH in pregnancies; universal screening should be considered as impaired thyroid function may predispose to miscarriage. KEY WORDS: Hypothyroidism, tri-iodothyronine{T3}, Thyroxin{T4} and TSH hormone, recurrent pregnancy losses. INTRODUCTION:Thyroid disorders are among the common endocrine disorders in pregnant women. It is now well established that not only overt hypothyroidism but also subclinical thyroid dysfunction can have adverse effects on fetal and maternal outcome. Maternal hypothyroidism during pregnancy raises serious concern about long-lasting psycho-neurologic consequences for the progeny, due to the risk of insufficient placental transfer of maternal thyroid hormones to the developing fetus during the first half of gestation. 1 The risk for miscarriage increased by 15% for each 1mlU/l elevation of the TSH level on the basis of logistic regression analysis. 2 During the last decade there has been an increasing appreciation of the incidence of thyroid dysfunction during pregnancy as well as the resultant adverse maternal and fetal effects. 3,4,5 In the hope that many of these adverse effects could be prevented or ameliorated by early detection and appropriate treatment the proposal to implement screening for thyroid function during pregnancy deserves consideration. To validate the need of antenatal screening for maternal thyroid dysfunction this study was undertaken to the prevalence of thyroid dysfunction among pregnant women in India. Recurrent pregnancy loss (RPL) is defined as three or more consecutive spontaneous pregnancy
Background: ART centers are the corner stone for providing care to HIV patient and it is very essential part of HIV/AIDS control programme in India. Objectives: To study the satisfaction level of Beneficiaries and Attendants of the Children receiving care at ART centers. Methodology: A cross-sectional study was conducted with the help of Pre-designed, Pretested, Semi-structured questionnaire for Beneficiaries and legal guardian of Children receiving care at ART centers to assess the satisfaction level for services, using Likert Scale and PSQ-18 during the period between 01 January 2015-31 October 2015 .Simple random sampling for selection of ART centers and Sequential sampling for the Beneficiaries and legal guardian of the Children receiving care at ART centers. A total of 110 patients were included in the study. Results: In study sites, satisfaction with behaviour of staff was highest, 92 % and only 5 % were dissatisfied, 90 % of clients were satisfied with infrastructure and facilities, 83.6% of clients were satisfied with communication and interpersonal manner, lowest satisfaction 45%was observed for ART side effects and tolerance. On basis of PSQ18 Questionnaire the mean score for General Satisfaction was 3.18 (SD 0.71), Technical Quality 2.89 (SD 0.84), Interpersonal Manner 3.08 (SD 0.81), Communication 3.00(SD 0.85), Financial Aspects was 2.67 (SD 0.91), Time Spent during the visit, 2.99 (SD 0.92), for Accessibility and Convenience 2.52 (SD 0.91). Conclusions: overall Satisfaction level of beneficiaries was good, although there were some places for improvement i.e. traveling, waiting area.
Background: Critically ill eclampsia patients present a unique challenge to the obstetrician, anesthesiologist and intensivists. In developing countries, maternal mortality is still high due to lack of good maternal antenatal services and obstetric intensive care. This study aims to provide a comprehensive review for the management and outcome of critically ill eclampsia patients admitted in the obstetric intensive care unit (ICU), GMC, Bhopal.Methods: This study was a hospital based cross sectional study. The study included 145 eclampsia patients who were admitted in obstetric ICU for critical care management. For each eligible patient, sociodemograhic profile, indications of ICU admission, data on ICU interventions and maternal outcome were documented.Results: During study period, total obstetric admission were 19,815 and 14,731 live births. Out of 348 eclampsia patients, 145 patients were admitted to the obstetric ICU, giving an ICU admission rate of 9.8/1000 live births. 98.03% patients were unbooked referred obstetric emergencies.The average duration of stay in obstetric ICU was 5.4+3.1 days. 72.9% patients had antepartum eclampsia, 17.2% patients had postpartum eclampsia and 10.8% patients had intrapartum eclampsia. 41% patients received mechanical ventilation, 90% patients received oxygen and advanced monitoring, 48.6% patients received vasoactive drugs and 53.7% patients received blood transfusions. There were 26 maternal deaths giving a case fatality rate of 17.93%.Conclusions: Early referral of eclampsia patients or at risk patients to a tertiary care centre may help to reduce maternal morbidity and mortality. Early diagnosis and prompt treatment through a multidisciplinary team in an ICU setting can prevent complications and reduce morbidity and mortality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.